Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Biomol Biomed [Internet]. 2022 Apr. 1 [cited 2024 May 1];22(2):300-1. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/6419